INTRODUCTION
Gliomas represent approximately 70% of all paediatric brain tumours and the majority of these will be of astrocytic lineage. Low-grade astrocytoma (LGA) comprise predominantly pilocytic astrocytoma (WHO grade I) and, less commonly, diffuse astrocytoma (WHO grade II). Malignant or high-grade astrocytoma (HGA) include anaplastic astrocytoma and glioblastoma multiforme (WHO grades III and IV, respectively) and account for approximately 20% of paediatric astrocytoma. 1 Treatment options for paediatric glioma patients are limited. Although LGA are relatively slow-growing tumours which can often be cured through surgical resection, a significant proportion of cases will recur. Both LGA and HGA tumours which are disseminated or located in deep-seated or functionally critical areas are inoperable, especially those in the brainstem, including diffuse intrinsic pontine glioma (DIPG). 2 Adjuvant radiotherapy can contribute to significant neurological morbidity and conventional chemotherapy with alkylating agents has achieved limited improvement in progression free or overall survival. [3] [4] [5] [6] Paediatric astrocytomas differ considerably from their adult counterparts in the spectrum and frequency of their mutations. Many of the common genetic abnormalities in adult glioma are not present in the paediatric tumours, particularly amplification and/or overexpression of EGFR and VEGRF and deletion/mutation of PTEN and hence, small tyrosine kinase inhibitors targeting these receptors are ineffective for treating paediatric astrocytoma.
Recently, high-throughput screening, particularly whole genome and transcriptome sequencing analyses, have identified new oncogenic mutations in BRAF, FGFR1, ACVR1 and PPDM1 and amplifcation and/or overexpression of MYB/MYBL1 and IGF1R in paediatric
LGA and HGA, which could be exploited in novel therapeutic interventions.
For example, upregulation of the RAS-RAF-MEK-ERK pathway through activating mutations is frequent in all grade of paediatric astrocytoma. In LGA, the predominant molecular alteration (present in >70% cases) is an oncogenic KIAA1549-BRAF fusion protein which lacks the N-terminus regulatory domain of BRAF whilst retaining the Cterminus BRAF kinase domain. 7 Approximately 20% HGA (and a subset of grade II astrocytoma), harbour the V600E BRAF mutation, which is constitutively activated through a T to A mutation leading to a valine to glutamate substitution at residue 600. 8 LGA and 12% HGA. 7, 9, 10 Furthermore, rearrangements truncating the C-terminal miRNA negative-regulatory domain and/or amplification of the transcription factors MYB or MYBL1 have recently been reported in 25% of cerebral grade II diffuse astrocytoma. 7, 11, 12 Mutations in ACVR1, encoding a bone morphogenetic protein (BMP) type 1 receptor, have been identified in 32% DIPG and 12% mid-line HGA in conjunction with the histone H3.1pLys27Met mutation. 10, 13 Here, missense mutations are located in either the kinase domain or the inhibitory glycine-serine-rich domain and induce ligand-independent activation of the TGF-β signalling pathway and increased SMAD phosphorylation.
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DISCUSSION
The key principle in this approach, that of enhancing the prognosis of paediatric glioma patients using small molecules, focusses on exploiting the key genetic differences (outlined above) between adult and paediatric tumours. It has been shown for a number of key cellular pathways and biomolecular targets that the genetic differences of these two patient groups is significant, which therefore presents cancer researchers with a unique approach to use them in development of therapies. For example, protein kinases have enjoyed much success in the treatment of cancer over the past couple of decades, but the three-dimensional structure of the kinase in its biologically relevant conformation, and indirectly its primary sequence, is of utmost importance for the ability of drugs to bind and inhibit the kinase. 16 Moreover, sensitivity to anticancer drugs is compromised when mutations in the target occur which cause the shape and functionality of the active site to change, since the drug no longer binds and elicits a response. This is the crux of the problem when trying to treat paediatric glioma with drugs designed for adult glioma. If the biological target in the paediatric cancer cell is no longer reminiscent of that for which the drug was originally designed (in the adult), it will not work as intended. Furthermore, unwanted side-effects may result instead. Therefore, through the rational design of new compounds using the mutated target as a template, the development of an arsenal of paediatric-selective drugs could be achieved, which are more efficient than existing treatments for paediatric tumours.
Aberrant expression and mutated targets
Based on this set of tumour types, there appears to be two main pathways of relevance to enable the potentially selective-treatment of paediatric glioma: 1) the RAS-RAF-MEK-ERK pathway; 2) the PI3K/AKT/mTOR pathway. Whilst other targets have been outlined above, the principle behind our rationale will be exemplified with a few individual cases below.
Small molecules kinase inhibitors for the treatment of paediatric glioma
Although this review focusses specifically on the common genetic differences between adult and paediatric patients, small molecule inhibitors of cellular pathways involved in gliomagenesis in children, in general, has been the subject of an excellent review, and includes the current challenges to small molecule therapy, and future directions in the use of this therapy. 17 Similarly, the recent advances in molecular interrogation of paediatric low grade gliomas have shown a small number of recurring genetic mutations in these tumours that might be exploited therapeutically.
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V600E BRAF inhibitors
Raf kinases participate in the RAS-RAF-MEK-ERK signal transduction cascade and an exemplar inhibitor of the Raf-kinase is sorafenib. However, in the context of this review, the V600E BRAF mutation, present in approximately 20% HGA, 19 is an excellent case in point to highlight the way in which paediatric glioma treatment can potentially be enhanced through the design of mutation-specific small molecules (the V600E mutation results in an amino acid substitution at position 600 in BRAF, from valine (V) to glutamic acid (E)). Inhibition of BRAF signalling blocks proliferation of the cancer cells and induces apoptosis, events which have validated V600E BRAF as a therapeutic target. 20 For example, recent BRAF-targeted therapies, such as vemurafenib (aka PLX4032, Figure 1 ), have shown great promise in treating V600E-dependent melanomas, such that melanoma cells without these mutations are not inhibited by vemurafenib, 21 but in theory the concept could be extrapolated to other cancers with a V600E-dependence, including paediatric glioma. Evidently, the chemical differences in the structures of vemurafenib and other wild-type BRAF inhibitors is sufficient to enable vemurafenib to inhibit the mutated protein over the wild-type protein, presumably due to increased interactions between the drug and its mutated target (see examples below).
Moreover, the structurally related compound, PLX4720 (Figure 1 ), is also a potent and selective inhibitor of V600E BRAF with an IC50 of 13 nM. This analogue has also been shown to be equally potent to c-Raf-1 (Y340D and Y341D mutations); it possesses 10-fold selectivity for the V600E BRAF mutation over wild-type B-Raf. 22 Structurally vemurafenib and PLX4720 are very similar, the only difference being the ring substituent at the 5-position of the 7-azaindole ring, therefore it is not too surprising that they are both capable of inhibiting the mutant protein in a similar manner.
In addition, PLX4720 has been shown to significantly increase the survival of mice transplanted with human astrocytoma cells, 19 and it has also been demonstrated that using PLX4720 in combination with PD0332991 (a CDK inhibitor) further extends survival relative to either monotherapy alone.
Based on the clear importance of developing new V600E BRAF inhibitors with increased potency and pharmacokinetic profiles, researchers at The Institute of Cancer Research, UK, developed a series of novel and potent BRAF inhibitors with nanomolar activity by way of judicious alterations to the central aromatic ring (Figure 2, 1) . 23 In their work, they proposed an analogous binding mode of their compounds to V600E BRAF based on the crystal structure of wild-type BRAF with sorafenib, and in doing so, they were able to exploit a lipophilic pocket in the binding site which would be available to accommodate the newly introduced ring substituents. All but two of the compounds prepared possessed activity that inhibited the oncogenic BRAF mutation, and in particular compounds 2 and 3 possessed IC50 values of 1nM, results which clearly demonstrate the importance of these ring modifications in being able to inhibit V600E BRAF selectively. Importantly, several of the compounds studied achieved over 10-fold increase in activity compared to sorafenib against BRAF, results that were achieved through elaboration of the central phenyl (see 1) ring to capitalise on the changes to the structure and conformation of the mutant kinase. and are selective over wild-type BRAF. 24 X-ray crystallographic studies on one of the compounds revealed that they appear to bind to the ATP binding cleft of the kinase in its active conformation, following which, a structure-activity programme was initiated on a family of naphthol compounds, resulting in compound 4 being the best candidate, which not only had significant selectivity for V600E BRAF over wild-type BRAF, but also had selectivity over other kinases too. Again, ring-substituents appeared to be important for selective V600E BRAF inhibition, and the authors were able to identify what they believed to be a BRAF/ V600E BRAF specificity pocket into which these ring-substituents were positioned. This information could give rise to further rounds of compound development to provide extremely selective V600E BRAF inhibitors. Despite the knowledge that their previous compounds 5 and 6 bind to the kinase in a DFGout conformation (see Box), 26 crystal structure analysis of 7 bound to a V600E BRAF model protein (EphB4: which has high binding site homology to V600E BRAF) confirmed that 7 binds in a DFG-in conformation (see Box). 26 Using this information, structural exploration began by making modifications to the A-and C-rings (Figure 4 
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In addition to the experimental compounds described above, there have also been clinical trial studies performed on a relatively large number of V600E BRAF mutant kinases, and many of the compounds are now commercially available for research purposes; the subject of 'B-Raf inhibitors: from bench to bedside' has also recently been reviewed. 
KIAA1549-BRAF
In both normal and tumour cells which express wild-type BRAF, V600E BRAF inhibitors induce paradoxical activation of MAPK signalling which is mediated through heterodimerisation with CRAF. 28 Similarly, cells expressing the KIAA1549-BRAF fusion protein demonstrate resistance and enhanced phosphorylation of MEK and ERK to first generation V600E BRAF inhibitors, including PLX4720 (Figure 1) . 21 This fusion protein lacks the regulatory RAS-binding N-terminus domain and is constitutively activated through homodimerisation. The KIAA1549-BRAF fusion however is responsive to a secondgeneration selective BRAF inhibitor (PLX PB-3 -structure unavailable) that, unlike vemurafenib, does not induce activation of wild-type BRAF.
This additional complication therefore highlights the difficulties of using a 'one-method fits all' approach for the development of compounds to treat paediatric glioma. It is becoming clear that targeted treatment regimens for BRAF-altered paediatric astrocytomas are necessary, and that therapies must be tailored to the specific mutation and distinct mechanisms of action of the mutant kinase for each patient. Such a scenario may well require radical advances in the way in which patients are assessed prior to treatment.
Other kinases
With this approach in mind, arguably other kinases relevant to tumour progression could be treated in the same manner, i.e. exploiting any identified mutations to design selective treatments. For example, it is known that PDGFR-α activates the RAS-RAF-MEK-ERK pathway, whereby it is amplified in 30% of paediatric glioma, and of those 14% have mutations. 29 Similarly, FGFR1 is a potential new target which has mutations in subsets of paediatric astrocytoma and glioblastoma multiforme. 30 Drug targeting of FGFR fusions has shown promising results and should soon be translating into clinical trials, and further understanding of the diverse mechanisms of FGFR ought to shed light on the impact of FGFR-derived therapy in the future. 30 The PI3K/AKT/mTOR pathway is an intracellular signalling pathway important in apoptosis, and consequently cancer, and the pathway is upregulated in both low and high grade astrocytoma. Within this pathway, a number of targets have been identified which are currently under examination.
IGF1R
The insulin-like growth factor 1 receptor (IGF1R) has been identified as a potential therapeutic target in paediatric glioblastoma due to gene amplification and high levels of IGF2 expression in some tumour samples. 31 In 2011, Bielen and co-workers evaluated the therapeutic potential of targeting this receptor by carrying out in vitro and in vivo preclinical studies using the specific IGF1R inhibitor NVP-AEW541 ( Figure 5 ). GI50 values of 5-6μM, and concurrent inhibition of receptor phosphorylation were observed along with hallmarks of PI3K inhibition after treatment with the compound. 31 Furthermore, their studies show that cotreatment of cells with NVP-AEW541 and imatinib resulted in a highly synergistic interaction in vitro compared with either agent alone. Identifying other kinases that may also be actively involved in paediatric glioblastoma cell lines will also help to design appropriate combination strategies to enhance IGFR1 inhibitor treatment. Hütt-Cabezas has recently reviewed the topic in a paper titled 'Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target', 32 and the importance of this pathway is also important in children with hematologic malignancies too. 33 Based on the pressing need to develop new inhibitors for mTOR, a number of researchers are currently identifying and developing novel small molecules against this, and related, targets.
For example, Lin and co-workers have developed a series of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives (9, Figure 6 ) as potent (nanomolar) PI3K/mTOR dual inhibitors. 34 Basing their compounds on a 4-methylpyridopyrimidinone scaffold the researchers hoped to identify a new inhibitor template that could address some of the issues with current treatments. Upon examining the co-crystal structure of 4-methylpyridopyrimidinone and PI3K they noticed that there was no direct interaction between the nitrogen atom at N-1 and PI3K, which immediately identified a good starting point to diversify the scaffold (see R 1 on
9)
. 34 This approach aligns well with the concept of designing new inhibitors for mutant targets and harnessing an under-exploited interaction to yield potent inhibitors. Their series of compounds, which turned out to be dual PI3K/mTOR inhibitors, had potent nanomolar IC50s which were comparable to a related compound in Phase two clinical trials, as well as acceptable cellular activities and pharmacokinetic profiles. Importantly, the authors suggest that identifying this series gives rise to a broader chemical space becoming available and thus improved opportunities for developing anti-tumour agents and advancing them into clinical trials.
Conversely, Lee and co-workers explored a series of N-7-methyl-imidazolopyrimidines based on the hypothesis that the N-7-methyl substituent on the imidazolopyrimidine motif would impart selectivity for mTOR over the related PI3K alpha and delta kinases. (10, Figure 6 ) also show potent mTOR inhibition with selectivity toward both PI3 alpha and delta kinases. The most potent compound (10) possesses a Ki of 2 nM against mTOR inhibition, and significant selectivity (>2900x) over PI3 kinases, as well as possessing excellent potency in cell-based assays. 35 The syntheses of PI3K/Akt/mTOR signaling pathway inhibitors has also recently been reviewed.
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Other targets
Diffuse gliomas in adults generally arise in cerebral white matter, whereas paediatric cases often arise in deep cerebral structures, most commonly the brainstem. In contrast to adult tumours, childhood tumours commonly have mutations in histone H3 genes (H3F3A and HIST1H3B), usually encoding a p.Lys27Met substitution. 37 Recent studies have also recognised recurrent mutations of the ACVR1 gene in these tumours, thereby highlighting another important difference between gliomas affecting children and adults and a potential target for developing much needed therapies. 15 Taylor et al. have identified mutations in the ACVR1 gene, which encodes a type I activin receptor serine/threonine kinase (ALK), in 21% of DIPG samples. 15 Overall, the researchers identified 11 of 52 DIPG samples (21%)
possessing mutations in ACVR1 which appear to be highly specific to DIPG. . 38 However, this is a disease which has mutations in the germ line of individuals which are identical to mutations found in cancer and so these new lead compounds may find success in the treatment of childhood DIPG too.
In their work identifying all the protein-coding genes in certain tumours, Zhang et al. activity. 40 The best compound, SPI-001, exhibits structural diversity from other known PPM1D inhibitors and represents a new scaffold for this target. The compound demonstrates very strong inhibition against PPM1D with a sub-micromolar IC50 value (0.48 ± 0.04 µM).
SPI-001 suppresses the cell proliferation of MCF7 cells by inducing apoptosis, whilst structure-activity relationships indicated that the two hydrophobic moieties (TES and TBS in SPI-001) are important for inhibitory activity.
Furthermore, in 2014, The Institute of Cancer Research, UK, identified 2,4-bisarylthiazoles (e.g. 11, Figure 8 ) as being able to cause highly selective apoptosis in PPM1D amplified celllines. 41 Having optimized the 2,4-bisarylthiazole structure for selective growth-inhibition of the PPM1D amplified cell-line SMOV2 versus the non-amplified cell-line TOV21G, the group decided to assess how general this PPM1D amplification phenotype was. In doing so, compound 11 was examined in a 5-day sulforhodamine B (SRB) growth inhibition assay against various PPM1D amplified and non-amplified cell-lines. None of the non-amplified cell-lines were sensitive to 11, whilst all three PPM1D amplified cell-lines displayed high sensitivity to the same compound, leading to potent low nanomolar growth-inhibition. Their class of compound displays clear structure-activity relationships, with particular importance for the cellular activity associated with the 4-fluorophenyl substituent.
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WHERE NEXT?
Due to the increasing number of genetic variations that continue to be identified between adult and paediatric glioma, it is becoming clear that tailored therapies to an individual child's genetic requirements may be desirable. Identifying suitable biomarkers to these variations would therefore be of utmost importance in order to maximise the efficacy of treatment. That said, it can take up to 15 years to get a drug from the experimental stages to the clinic, therefore, identifying mutant targets and developing inhibitors of them as soon as possible is crucial so that an arsenal of compounds can be available for all contingencies.
However, monotherapy alone using selective kinase (or other target) inhibitors, is unlikely to prove completely effective due to intrinsic or acquired resistance problems seen with other anticancer drugs. Nevertheless, overcoming such limitations could possibly be mitigated using combination treatments which target alternative oncogenic pathways, using either current drug combinations or new drugs with existing ones.
LEGENDS
Figure 1
V600E BRAF inhibitors.
Figure 2
Other kinase inhibitors and the phosphatase inhibitors SPI-001 and 11.
